A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma
PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment
87
Participants
Timeline
Start Date
October 31, 2014
Primary Completion Date
August 31, 2015
Study Completion Date
August 31, 2015
Conditions
B-cell Non Hodgkin's Lymphoma
Interventions
DRUG
HLX01
DRUG
Rituximab
All Listed Sponsors
lead
Shanghai Henlius Biotech
INDUSTRY
NCT02584920 - A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma | Biotech Hunter | Biotech Hunter